INFLAMMATIX, INC.
StreetZero Signal 81
About INFLAMMATIX, INC.
Inflammatix is a molecular diagnostics company developing point-of-care tests that profile a personβs immune response to quickly determine bacterial and viral infections and help curb antimicrobial resistance. Its Myrna system and InSep test target sepsis and acute infections, with the ViraBac EZ fingerstick test also in development. The company is headquartered in Sunnyvale, California and was founded in 2016.
LATEST FUNDINGPrivate Placement
$47.4M
Announced 2026-11-19
TOTAL RAISED$200M+
IN THE NEWS
- π Inflammatix nets $102M to advance its immune system tests for infectious diseases | Fierce Biotech
- π Inflammatix Valuation, Funding & Investors | Multiples
- π Inflammatix Announces $32 Million in Series C Funding - Inflammatix
- π Inflammatix, Inc.
- π Inflammatix, Inc. Company Overview, Contact Details & Competitors | LeadIQ
EMPLOYEESβ
FOUNDED2016
HQSunnyvale, CA, United States
Industry
Biotechnology
Tags
BiotechnologyDiagnosticsMolecular DiagnosticsPoint-of-Care
Investors
Key highlights
- Secured $102M in Series D financing led by D1 Capital Partners to advance commercialization.
- Closed $57M Series E round in September 2024 led by Khosla Ventures and Think.Health.
- Total private capital raised exceeds $200 million over eight years.
- Developing Myrna system and InSep test for sepsis and acute infections with FDA submission underway.
- Backed by multiple institutional investors including Northpond Ventures and OSF Healthcare Ventures.
Ask StreetZero about INFLAMMATIX, INC.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account